Sanofi-aventis

Sanofi

Mitsubishi Pharma Corporation

Mitsubishi Tanabe Pharma Corporation

Sanofi-synthelabo

Antonio Almario Garcia

Yulin Chiang

Ahmed Abouabdellah

Christian Hoornaert

Adrien Tak Li

Alistair Lochead

Mourad Saady

Philippe Yaiche

Jacques Froissant

Patrick Andre Lardenois

Yannick Evanno

Zhongli Gao

Alain Nedelec

Thierry Gallet

Philippe Burnier

Nathalie Rakotoarisoa

Roy J Vaz

Danielle De Peretti

Pascal George

Alain Gueiffier

Tak Adrien Li

Qiuxia Zhao

Kazutoshi Watanabe

Jonathan Reid Frost

David Machnik

Ryoichi Ando

Matthieu Barrague

Fumiaki Uehara

Séverine Marguerie

Jean Jeunesse

André Malanda

Antoine Ravet

Aya Shoda

Frédéric Puech

Anne Olivier

Christophe Pacaud

Keiichi Arimoto

Cecile Enguehard-Gueiffier

Mathieu Barrague

Cécile Enguehard

Frederic Peuch

Sylvain Cote-Des Combes

Larry Davis

Jean-François Gilbert

The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R, R, R, R, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.

6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof

Compounds of formula (I): wherein R, R, R, R, R, and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

Polysubstituted 2-aryl-6-phenylimidazo[1,2-A]pyridine derivatives, and preparation and therapeutic use thereof

Compounds of formula (I): wherein R, R, R, R, Rand X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

[object Object]

Substituted tricyclic derivatives

The invention relates to a compound having general formula (I): Wherein m, Rand Rare as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which include in a non-limiting manner, pain, eating disorders, neurological and psychiatric pathologies, among other disorders.

Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme

The invention relates to a compound of formula (I): Wherein m, n, X, Y, R, R, Rand Rare as defined herein. The invention also relates to the use of same in therapeutics.

Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of disease and other pathological conditions are not generated and the incidence of the disease is greatly reduced.

Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors

The present invention is related to a compound of formula (I) wherein R, R, Rand Rare as defined herein, or an addition salt of an acid thereof, the pharmaceutical composition and preparation thereof, and the therapeutic use thereof in the treatment or the prevention of diseases involving Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof

The present invention comprises peridinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of a large variety of diseases and other pathological conditions are not generated and the incidence of the disease is greatly reduced.

Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors

The invention relates to a compound having general formula (I): Wherein n, A, R, R, and Rare as defined herein. The invention also relates to methods of preparation of compound of formula (I) as well as its use in therapeutics.

Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics

Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme

The present invention provides a compound of the formula (I): in which R, R, R, A and n are described and set forth more fully herein. Also provided are their preparation and their application in therapy.

Arylalkylcarbamate derivatives and production thereof

The invention relates to therapeutic uses of a pyrimidone derivative represented by formula (I) or a salt thereof:  Wherein X, Y, R1, R2, m and n are as defined herein. Specifically, a medicament comprising the said derivative or a salt thereof as an active ingredient is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3&#x3b2; such as Alzheimer's disease.

Growing community of inventors

Chatenay Malabry, France

Antonio Almario Garcia